236 
Market Cap
Stock Chart
Prana Biotech - 30 Day Poll
Recent BLOGS About Prana Biotech Add New
Latest Company News
|
PRANA BIOTECHNOLOGY LIMITED : Dr Rudy Tanzi to Discuss PBT2 Trial on Thursday ...
4-traders - May 10, 2012 Melbourne - 9 May, 2012: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that Professor Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Prana's Chief Scientific Advisor will give a Plenary ...
|
|
Prana Chief Scientific Advisor to Give Plenary Lecture at Alzheimer's ...
MarketWatch (press release) - May 9, 2012 MELBOURNE, AUSTRALIA, May 09, 2012 (MARKETWIRE via COMTEX) -- Prana Biotechnology (UTD:PRAN) (asx:PBT) today announced that Professor Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Prana's Chief ...
|
|
Prana Comments on Archives of Neurology Publication Which Highlights Critical ...
SYS-CON Media (press release) - May 1, 2012 By Marketwire . MELBOURNE, AUSTRALIA -- (Marketwire) -- 05/01/12 -- Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today commented on the publication of new data of relevance to the current clinical trial, testing Prana's PBT2 as a treatment for ...
|
|
Prana Enrolls First Patient in the "Reach2HD" Phase II Huntington Disease Trial
MarketWatch (press release) - Apr 30, 2012 MELBOURNE, AUSTRALIA, Apr 30, 2012 (MARKETWIRE via COMTEX) -- Prana Biotechnology (UTD:PRAN) (asx:PBT) today announced that the first patient has been dosed in the "Reach2HD Trial" - a 6 month Phase IIa clinical trial testing PBT2, the Company's drug ...
|
Website
Videos related to Prana Biotech
Company Profile
Prana Biotechnology Limited (Prana) is a development-stage company researching pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses.
Lead compound: Prana has compounds in Phase II clinical trials - Prana’s lead Alzheimer’s Disease compound, PBT2, has already completed a Phase IIa study in early Alzheimer’s Disease patients and has demonstrated safety and tolerability. In addition, PBT2 showed significant improvement in Executive Function, an important aspect of cognitive performance, and reduced the levels of Abeta in the spinal fluid of patients. Abeta is a key protein associated with Alzheimer’s Disease.
Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts.
The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. Prana’s activities are focused within Australia and cover research into Alzheimer’s disease and other age-related degenerative disorders.
Finance Sept 09:
Prana Biotech reported net loss of $6.43m for the year ended 30 June 2011
Rights issue in March 2011 raised $6.1 million.
As of June 2011 the consolidated entity’s cash position was approx. A$8.8M